Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
5.69
+0.04 (0.62%)
At close: Jan 21, 2025, 4:00 PM
5.85
+0.16 (2.81%)
After-hours: Jan 21, 2025, 5:24 PM EST
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 133 employees as of December 31, 2023. The number of employees increased by 10 or 8.13% compared to the previous year.
Employees
133
Change (1Y)
10
Growth (1Y)
8.13%
Revenue / Employee
$112,594
Profits / Employee
-$897,662
Market Cap
349.57M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 133 | 10 | 8.13% |
Dec 31, 2022 | 123 | 30 | 32.26% |
Dec 31, 2021 | 93 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
GLUE News
- 15 days ago - Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - GlobeNewsWire
- 6 weeks ago - Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewsWire
- 3 months ago - This Biotech Stock Has Doubled Its Value Today—Here's Why - Investopedia
- 3 months ago - Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - GlobeNewsWire